EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische Studie

Targeted Oral Peptide Icotrokinra for Psoriasis Involving High-Impact Sites

Melinda Gooderham, Edward Lain, Robert Bissonnette, Yu-Huei Huang, Charles W Lynde, Matthias Hoffmann, Eingun James Song, Oliver Weirich, Raul Hernan Gabriel Ceitlin, Jessica H Rubens, Amy M DeLozier, Takayuki Ota und 5 weitere

NEJM Evidence · 25.11.2025 · 4 (12)

DOI: 10.1056/evidoa2500155 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift NEJM Evidence, erschienen am 25.11.2025. Verfasst von Melinda Gooderham und 16 weiteren Autor:innen. Beteiligte Einrichtung: SKiN Centre for Dermatology, Department of Medicine at Queen's University and Probity Medical Research, Peterborough, ON, Canada. Hauptthemen laut MEDLINE: Psoriasis. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 47 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisHumansDouble-Blind MethodMaleFemaleMiddle AgedAdultTreatment OutcomeAdolescentAdministration, OralSeverity of Illness IndexChildYoung AdultAged

Autor:innen und Institutionen

  • SKiN Centre for Dermatology, Department of Medicine at Queen's University and Probity Medical Research, Peterborough, ON, Canada.
  • Austin Institute for Clinical Research, Sanova Dermatology, Austin, TX, USA.
  • Innovaderm Research, Montreal, QC, Canada.
  • Department of Dermatology, Chang Gung Memorial Hospital and College of Medicine, Chang Gung University, Taoyuan City, Taiwan.
  • Department of Medicine, University of Toronto, Toronto, ON, Canada.
  • The Lynde Institute for Dermatology and Lynderm Research Inc., Markham, ON, Canada.

Zitieren

APA

Gooderham, M., Lain, E., Bissonnette, R., Huang, Y. H., Lynde, C. W., Hoffmann, M., Song, E. J., Weirich, O., Ceitlin, R. H. G., Rubens, J. H., DeLozier, A. M., Ota, T., Hsu, M. C., Li, S., DeKlotz, C. M. C., Nunes, F., & Warren, R. B. (2025). Targeted Oral Peptide Icotrokinra for Psoriasis Involving High-Impact Sites. NEJM Evidence, 4(12). https://doi.org/10.1056/evidoa2500155

Vancouver

Gooderham M, Lain E, Bissonnette R, Huang YH, Lynde CW, Hoffmann M, et al. Targeted Oral Peptide Icotrokinra for Psoriasis Involving High-Impact Sites. NEJM Evidence. 2025;4(12). doi:10.1056/evidoa2500155

BibTeX
@article{Gooderham2025,
  author = {Gooderham, Melinda and Lain, Edward and Bissonnette, Robert and Huang, Yu-Huei and Lynde, Charles W and Hoffmann, Matthias and Song, Eingun James and Weirich, Oliver and Ceitlin, Raul Hernan Gabriel and Rubens, Jessica H and DeLozier, Amy M and Ota, Takayuki and Hsu, Ming-Chun and Li, Shu and DeKlotz, Cynthia M C and Nunes, Fabio and Warren, Richard B},
  title = {Targeted Oral Peptide Icotrokinra for Psoriasis Involving High-Impact Sites},
  journal = {NEJM Evidence},
  year = {2025},
  volume = {4},
  number = {12},
  doi = {10.1056/evidoa2500155}
}
Kostenlos starten →